Compare RKT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | NVAX |
|---|---|---|
| Founded | 1985 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0B | 1.1B |
| IPO Year | 2020 | 1995 |
| Metric | RKT | NVAX |
|---|---|---|
| Price | $19.22 | $6.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 8 |
| Target Price | ★ $19.46 | $9.75 |
| AVG Volume (30 Days) | ★ 22.9M | 3.3M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $6,098,944,000.00 | $1,064,651,000.00 |
| Revenue This Year | $15.41 | $58.91 |
| Revenue Next Year | $72.61 | N/A |
| P/E Ratio | ★ N/A | $3.22 |
| Revenue Growth | ★ 41.68 | 20.27 |
| 52 Week Low | $10.06 | $5.01 |
| 52 Week High | $22.56 | $11.55 |
| Indicator | RKT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 50.27 |
| Support Level | $17.76 | $6.36 |
| Resistance Level | $19.41 | $6.76 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 60.54 | 78.52 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.